Treatment of endometriosis, angiogenesis and/or endometrial lesion growth

Abstract

Synuclein-gamma (SNCG) inhibitors are useful for inhibiting or treating angiogenesis, endometriosis and/or endometrial lesion growth. They also potentiate efficacy of other hormonal agents in treating angiogenesis, endometriosis and/or endometrial lesion growth.

1 - 21 . (canceled) 
     
     
         22 : A pharmaceutical composition for inhibition or treatment of endometriosis, angiogenesis, endometrial lesion growth or a combination thereof, the composition comprising a γ-synuclein (SNCG) inhibitor in an amount effective to inhibit or treat endometriosis, angiogenesis, endometrial lesion growth or a combination thereof. 
     
     
         23 : The composition according to  claim 22  in combination with an anti-angiogenesis agent or hormonal agent for inhibiting angiogenesis, endometriosis or endometrial lesion growth. 
     
     
         24 : The composition according to  claim 22 , wherein the SNCG inhibitor is combined with a hormonal agent and the hormonal agent comprises a Gonadotropin-Releasing Hormone GnRH agonist or antagonist. 
     
     
         25 : The composition according to  claim 22 , wherein the SNCG inhibitor comprises a synthetic peptide, a portion thereof or a mimetic thereof, the synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO: 1. 
     
     
         26 : The composition according to  claim 22 , wherein the SNCG inhibitor comprises a synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO:1. 
     
     
         27 : The composition according to  claim 22 , wherein the SNCG inhibitor comprises a synthetic peptide comprising an amino acid sequence as set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6. 
     
     
         28 : The composition according to  claim 22 , wherein the SNCG inhibitor comprises a synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO:2. 
     
     
         29 . (canceled) 
     
     
         30 : The composition according to  claim 22  further comprising a pharmaceutically acceptable vehicle. 
     
     
         31 : A pharmaceutical composition for inhibition or treatment of endometriosis, angiogenesis, endometrial lesion growth or a combination thereof, the composition having a formula:
   Y-Z   wherein Y comprises a γ-synuclein (SNCG) inhibitor; and   wherein Z comprises a compound linked to Y that enhances the performance of Y.   
     
     
         32 : The composition according to  claim 31 , wherein Z comprises a targeting agent, a second agent for treatment of cancer or endometriosis, an agent which enhances solubility, absorption, distribution, half-life, bioavailability, stability, activity and/or efficacy, or an agent which reduces toxicity or side effects of the composition. 
     
     
         33 : The composition according to  claim 31  further comprising Q linked to Y-Z wherein Q is identical to Z or different from Z and wherein Q comprises a targeting agent, a second agent for treatment of cancer or endometriosis, an agent which enhances solubility, absorption, distribution, half-life, bioavailability, stability, activity and/or efficacy, or an agent which reduces toxicity or side effects of the composition. 
     
     
         34 : The composition according to  claim 31  further comprising a pharmaceutically acceptable vehicle. 
     
     
         35 - 36 . (canceled) 
     
     
         37 : A commercial package comprising a γ-synucleic (SCNG) inhibitor and instructions for its use to inhibit or treat endometriosis, angiogenesis, endometrial lesion growth or a combination thereof. 
     
     
         38 : The commercial package according to  claim 37  further comprising an anti-angiogenesis agent or hormonal agent for inhibiting angiogenesis, endometriosis or endometrial lesion growth. 
     
     
         39 : The commercial package according to  claim 38 , wherein the SNCG inhibitor is combined with a hormonal agent and the hormonal agent comprises a Gonadotropin-Releasing Hormone (GnRH) agonist or antagonist. 
     
     
         40 : The commercial package according to  claim 37 , wherein the SNCG inhibitor comprises a synthetic peptide, a portion thereof or a mimetic thereof, the synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO:1. 
     
     
         41 : The commercial package according to  claim 37  further comprising a pharmaceutically acceptable vehicle. 
     
     
         42 : A method of inhibiting or treating endometriosis, angiogenesis or endometrial lesion growth or a combination thereof, the method comprising administering to a subject a γ-synuclein (SNCG) inhibitor in an amount effective to inhibit or treat endometriosis, angiogenesis or endometrial lesion growth or a combination thereof. 
     
     
         43 : The method according to  claim 42 , wherein an anti-angiogenesis agent or hormonal agent for inhibiting angiogenesis, endometriosis or endometrial lesion growth is administered with the SNCG inhibitor. 
     
     
         44 : The method according to  claim 42 , wherein the SNCG inhibitor is administered with a hormonal agent and the hormonal agent comprises a Gonadotropin-Releasing Hormone (GnRH) agonist or antagonist. 
     
     
         45 : The method according to  claim 42 , wherein the SNCG inhibitor comprises a synthetic peptide, a portion thereof or a mimetic thereof, the synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO:1. 
     
     
         46 : The method according to  claim 42 , wherein the SNCG inhibitor comprises a synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO:1. 
     
     
         47 : The method according to  claim 42 , wherein the SNCG inhibitor comprises a synthetic peptide comprising an amino acid sequence as set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6. 
     
     
         48 : The method according to  claim 42 , wherein the SNCG inhibitor comprises a synthetic peptide comprising the amino acid sequence as set forth in SEQ ID NO:2. 
     
     
         49 : The method according to  claim 42 , wherein the subject is mammalian.